Radiopharmaceutical company Cyclopharm (ASX: CYC) is set to begin commercial sales of its lung imaging device Technegas in the US, following the Food and Drug Administration’s (FDA) stamp of approval on September 30.
Read More
The XJO is expected to edge lower on open this morning following a small pullback in the U.S on Friday. Their futures sit marginally in the green. Markets remain indecisive. Last week, most of our sessions were dojis, where we whipsawed intraday to both shed gains and retake losses. Roughly 7,000 and 7,080 marks the
Read More
Following a successful strategy of acquiring wind-up businesses, tech company Rewardle (ASX: RXH) is set to offer micro investment services having acquired fintech Upstreet for pennies-on-the-dollar, just as the start-up was shutting down. Founded in 2019 within the Antler venture capital accelerator program, Upstreet originally set out to reward shoppers with fractional shares in Australian
Read More
Australian shares are expected to open higher this morning, following buying in US markets overnight. Overall, US economic data was seen as somewhat disinflationary overnight, which is what the stock market wants to see. The Australian market does remain in a downtrend however, which may cap any movement to the upside. Expect to see strength
Read More
Another rough week for the now very stale bond bulls that show a startling level of misunderstanding of inflation. The reality is something we have written about many, many times since our first early warning in June 2020
Read More
According to the US Food and Drug Administration (FDA), Precision Medicine, or “personalised medicine”, is a new way of tailoring disease care by considering people’s unique genes, environments, and lifestyles. The goal is to give the right treatments at the right time.
Read More